BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 21442635)

  • 21. [Correlation of JAK2V617F mutation burden with clinical features in patients with polycythemia vera and essential thrombocythemia].
    Liu HX; Tong CR; Cai P; Teng W; Wang H; Zhang Y; Zhu P
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):742-5. PubMed ID: 19549399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.
    Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL
    Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
    Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
    Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombin generation: a comparison of assays using platelet-poor and -rich plasma and whole blood samples from healthy controls and patients with a history of venous thromboembolism.
    Tappenden KA; Gallimore MJ; Evans G; Mackie IJ; Jones DW
    Br J Haematol; 2007 Oct; 139(1):106-12. PubMed ID: 17854314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hydroxyurea therapy increases plasma erythropoietin in patients with essential thrombocythaemia or polycythaemia vera.
    Johansson P; Andréasson B
    Clin Lab Haematol; 2006 Aug; 28(4):233-6. PubMed ID: 16898960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelets significantly modify procoagulant activities in haemophilia A.
    Wartiovaara-Kautto U; Joutsi-Korhonen L; Ilveskero S; Armstrong E; Lassila R
    Haemophilia; 2011 Sep; 17(5):743-51. PubMed ID: 21682825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platelets compensate for poor thrombin generation in type 3 von Willebrand disease.
    Szanto T; Nummi V; Jouppila A; Brinkman HJM; Lassila R
    Platelets; 2020; 31(1):103-111. PubMed ID: 30836803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombin generation and procoagulant phospholipids in patients with essential thrombocythemia and reactive thrombocytosis.
    Mignon I; Grand F; Boyer F; Hunault-Berger M; Hamel JF; Macchi L
    Am J Hematol; 2013 Dec; 88(12):1007-11. PubMed ID: 23873831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia.
    Ricksten A; Palmqvist L; Johansson P; Andreasson B
    Haematologica; 2008 Aug; 93(8):1260-1. PubMed ID: 18519514
    [No Abstract]   [Full Text] [Related]  

  • 34. Src tyrosine kinase preactivation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera.
    Randi ML; Brunati AM; Scapin M; Frasson M; Deana R; Magrin E; Fabris F; Donella-Deana A
    Blood; 2010 Jan; 115(3):667-76. PubMed ID: 19965650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera.
    Falanga A; Marchetti M; Vignoli A; Balducci D; Barbui T
    Exp Hematol; 2005 May; 33(5):523-30. PubMed ID: 15850829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clearance of circulating activated platelets in polycythemia vera and essential thrombocythemia.
    Maugeri N; Malato S; Femia EA; Pugliano M; Campana L; Lunghi F; Rovere-Querini P; Lussana F; Podda G; Cattaneo M; Ciceri F; Manfredi AA
    Blood; 2011 Sep; 118(12):3359-66. PubMed ID: 21705500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Global coagulation in myeloproliferative neoplasms.
    Tripodi A; Chantarangkul V; Gianniello F; Clerici M; Lemma L; Padovan L; Gatti L; Mannucci PM; Peyvandi F
    Ann Hematol; 2013 Dec; 92(12):1633-9. PubMed ID: 23820940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis.
    Alvarez-Larrán A; Arellano-Rodrigo E; Reverter JC; Domingo A; Villamor N; Colomer D; Cervantes F
    Ann Hematol; 2008 Apr; 87(4):269-76. PubMed ID: 17899078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia.
    Marchetti M; Tartari CJ; Russo L; Panova-Noeva M; Leuzzi A; Rambaldi A; Finazzi G; Woodhams B; Falanga A
    Am J Hematol; 2014 Jan; 89(1):68-73. PubMed ID: 24009132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.